The Klein Law Firm announces the commencement of an investigation of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) concerning possible violations of federal securities laws.

On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva (obeticholic acid), the Company’s treatment for primary biliary cholangitis (“PBC”), advising them that the drug has been tied to liver injuries and death among patients suffering from PBC. Then on September 21, 2017, the Food and Drug Administration issued a Safety Announcement that the drug “is being incorrectly dosed in some patients…resulting in an increased risk of serious liver injury and death.” The FDA noted that “In the 13 months after Ocaliva was approved in May 2016, FDA received reports of serious liver injury or death associated with Ocaliva.”

If you suffered a loss in Intercept and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/ICPT-Info-Request-Form-212.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.